18 November 2026 | Wednesday | News
Image Source: Public Domain
Cosentyx (secukinumab) doubled sustained remission rates and demonstrated steroid-sparing effects vs placebo in Phase III trial¹
Approval marks 11th US indication for Cosentyx, building on its decade-long established efficacy and safety profile across immune-mediated diseases¹
Cosentyx PMR indication already approved in EU; additional regulatory reviews ongoing, including in Japan
Novartis announced that the US Food and Drug Administration (FDA) approved Cosentyx (secukinumab) 150 mg for the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.¹ Cosentyx is the first and only anti-interleukin-17 (anti-IL-17) biologic approved for people living with PMR, a common inflammatory disease that primarily affects adults over 50, providing a new treatment option beyond long-term steroid use—the current standard of care, which may be associated with significant side effects and risks.¹⁻⁵
“The FDA approval of secukinumab in PMR marks a significant advancement for patients and physicians. Patients with PMR are at increased risk of poor outcomes related to steroids, and the prospect of months or years of additional steroids is disheartening,” said Prof. John Stone, MD, MPH, Professor of Medicine, Harvard Medical School, Massachusetts General Hospital, and global principal investigator for the REPLENISH trial. “For too long, treatment options beyond glucocorticoids have been limited. In the Phase III REPLENISH trial, secukinumab doubled the likelihood of sustained remission while helping patients taper off steroids, which should be the goal of PMR treatment.”
In the United States, there are approximately 966,000 people living with PMR—a disease characterized by acute pain and stiffness in the shoulders, neck, and hips.²˒⁶ PMR is commonly treated with steroids, but relapses are frequent, affecting up to 40% of patients in the first year.⁴ Long-term steroid use increases the risk of osteoporosis, cardiovascular disease, and diabetes.³ The approval of Cosentyx as the first anti-IL-17 biologic indicated for people with PMR offers rheumatologists an alternative to long-term steroid use based on more than a decade of clinical experience across immune-mediated diseases.¹
“PMR can make remarkably ordinary things hard: getting out of bed, getting dressed, lifting your arms, getting through the day. For years, patients have had too few treatment options,” said Seth Ginsberg, Co-Founder and President, Global Healthy Living Foundation and CreakyJoints. “The approval of secukinumab offers patients and their clinicians a new therapeutic option and the opportunity for more individualized care.”
“For more than a decade, Cosentyx has helped redefine what’s possible for people living with immune-mediated diseases, delivering meaningful outcomes across multiple conditions,” said Victor Bultó, President, US, Novartis. “With this approval in PMR, our 11th US indication for Cosentyx, we are expanding those benefits to a community that has had limited treatment options for far too long. This milestone reflects our commitment to continually investigate where our medicines can help patients most, extending the impact of proven innovations to new areas of significant unmet need.”
© 2026 Biopharma Boardroom. All Rights Reserved.